Research Article

Correlation of EGFR (Her1) expression with clinical features in sinonasal squamous cell carcinoma

Published: March 30, 2021
Genet. Mol. Res. 20(1): GMR18749 DOI:
Cite this Article:
(2021). Correlation of EGFR (Her1) expression with clinical features in sinonasal squamous cell carcinoma. Genet. Mol. Res. 20(1): GMR18749.


Prognosis of sinonasal squamous cell carcinoma (SNSCC) depends on TNM (Tumor, Node, Metastasis) staging, histological manifestations, and activity of cell-surface receptors (p53, Ki67, EGFR − Epidermal Growth Factor Receptor (ErbB-1; Her1). EGFR is the best- studied transmembrane tyrosine kinase receptor. The intensity of tumor cells division and the rate of their metastasis depend on EGFR. It also regulates the processes of angiogenesis. All this determines the severity of the course of the disease and the ability to predict its outcome. Depending on the speed of EGFR expression, targeted therapy may or may not be prescribed. The clinical picture and prognosis of SNSCC depends on the rate of EGFR expression. We conducted a prospective case study on 32 SNSCC patients treated at the National Ear Nose and Throat Hospital during two years (2011-2012). Clinical presentations and computed tomography scan imaging were analyzed and biopsy samples were examined to investigate EGFR activity (Her1). A semi quantification technique was used. The level of EGFR expression was correlated with disease staging. The rate of positive EGFR expression in SNSCC was 17/32; 8/32 scored 3+. EGFR was positive in 16/32 stage III patients. The EGFR-positive rate was higher in exophytic, advanced stage cancer, with neurological deficits and lymphadenopathy of the neck. EGFR expression was increased in 17/32 of sinonasal squamous cell carcinoma samples. Patients with more severe manifestations, including neurological symptoms, facial deformities and exophytic tumor growth had a significantly higher EGFR expression rate.